Long Ideas - This morning, PropThink featured an update on Ventrus Biosciences (NASDAQ: VTUS) post its second quarter results, noting that the company has enough cash to get … Continue Reading
Read now- Pfizer’s (NYSE:PFE) renal cell carcinoma treatment Torisel failed a study determining its capabilities in combination with Avastin. Torisel is approved as a monotherapy, but PFE … Continue Reading
Read now- After announcing an increased stock rebuyback program, Spectrum Pharmaceuticals (NASDAQ:SPPI) is up 4% this morning. SPPI’s board previously announced allowance for $25 million to repurchase … Continue Reading
Read nowLong Ideas - Ventrus Biosciences (NASDAQ:VTUS) released second quarter results last night, and notably, the company reported that it has $29 million in cash, enough to fund operations … Continue Reading
Read nowShort Ideas - Seattle Genetics (NASDAQ:SGEN) missed earnings expectations again, leaving analysts and investors uncertain about the company’s 2012 revenue guidance and beyond. Major shareholders may seek to … Continue Reading
Read now- Salix Pharmaceuticals (NASDAQ:SLXP) is moving ahead of the bell after it announced 2Q earnings and a major licensing deal yesterday. Salix entered into an agreement … Continue Reading
Read nowLong Ideas - Sucampo Pharmaceuticals (NASDAQ:SCMP) reported 2Q 2012 revenues of $16.7 million, up 19.2% year over year. Evidence that the company’s treatment for irritable bowel syndrome (IBS), … Continue Reading
Read now